Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Wed, 28.09.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, September 28, 2022
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth [ … ]
Wed, 28.09.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, September 28, 2022
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth [ … ]
Wed, 31.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 31, 2022
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ann [ … ]
Wed, 31.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 31, 2022
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ann [ … ]
Wed, 03.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 3, 2022
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth
Efficacy and safety data of pelabresib for potential treatment improvement in myelof [ … ]
Wed, 03.08.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 3, 2022
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth
Efficacy and safety data of pelabresib for potential treatment improvement in myelof [ … ]
Thu, 28.07.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 28, 2022
Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:0 [ … ]
Thu, 28.07.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 28, 2022
Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:0 [ … ]
Tue, 26.07.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 26, 2022
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)
Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 millio [ … ]
Tue, 26.07.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 26, 2022
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)
Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 millio [ … ]